fda glp-1 warning letters september 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading Beyond the Headlines: FDA Warning

To maximize weight loss while using a GLP-1 medication like semaglutide, its vital to combine the medication with lifestyle changes

The LactMed database explicitly warns that some brands of oral semaglutide contain the absorption enhancer salcaprozate sodium, which may enter milk and accumulate in infants

Eat more fiber Dietary fiber, especially soluble fiber found in fruits, vegetables, legumes, and whole grains, promotes the release of GLP-1

Providers may benefit from: Clear prescription workflows Transparent communication Educational support resources Ongoing coordination aligned with compliance standards Choosing the right partner helps practices deliver better patient experiences and maintain confidence in therapy programs

The post is an advertisement for a "6-in-1 health oral liquid" that claims to be Medsafe certified

Clinical trials and real-world data consistently show: Average weight loss of 1520% on semaglutide or tirzepatide Improvements in blood pressure, cholesterol, and blood sugar Reduced risk of developing type 2 diabetes and cardiovascular disease These outcomes are meaningful both for employee health and long-term cost avoidance